Biobehavioral Interactions between Endocannabinoid and Hypothalamicpituitary- adrenal Systems in Psychosis: A Systematic Review DOI
Marco Colizzi, Riccardo Bortoletto,

Giulia Antolini

и другие.

Current Neuropharmacology, Год журнала: 2023, Номер 22(3), С. 495 - 520

Опубликована: Авг. 3, 2023

Background: The diathesis-stress paradigm and the cannabinoid-hypothesis have been proposed as possible pathophysiological models of schizophrenia. However, they historically studied independently each other. Objective: This PRISMA 2020-compliant systematic review aimed at reappraising interplay between hypothalamic-pituitary-adrenal (HPA) axis endocannabinoid (eCB) system in psychosis- spectrum disorder risk outcome. Methods: All outcome clinical studies, concomitantly evaluating two systems psychosis-spectrum different stages illness, were gathered from electronic databases (Pubmed, Web Science, Scopus), discussed. Results: 41 eligible outputs extracted, focusing on least a biological measure (9 HPA-related studies: 4 eCB-interventional, 1 HPA-interventional, both HPA-interventional non-interventional, 3 non-interventional; 2 eCB-related non-interventional), environmental measures only (29 eCB- interventional, 28 genetic (1 study: non-interventional). Independent contributions aberrancies to physiopathology psychosis confirmed. Also, concomitant alterations systems, either genetically defined (e.g., CNR1 variation), biologically determined dysfunctional HPA or signaling), behaviorally imputed cannabis use, stress exposure, response), consistently reported psychosis. Further, complex biobehavioral perturbation was revealed not within use affecting eCB tone, exposure axis), but also across THC axis, childhood trauma signaling). Conclusion: There is need study systems’ mechanistic contribution order establish more refined relevance.

Язык: Английский

Enhancing Endocannabinoid Control of Stress with Cannabidiol DOI Open Access
Jeremy D. Henson, Luis Vitetta,

Michelle Quezada

и другие.

Journal of Clinical Medicine, Год журнала: 2021, Номер 10(24), С. 5852 - 5852

Опубликована: Дек. 14, 2021

The stress response is a well-defined physiological function activated frequently by life events. However, sometimes the can be inappropriate, excessive, or prolonged; in which case, it hinder rather than help coping with stressor, impair normal functioning, and increase risk of somatic mental health disorders. There need for more effective safe pharmacological treatment that dampen maladaptive responses. endocannabinoid system one main regulators response. A basal tone inhibits response, modulation this permits/curtails an active chronic deficiency associated pathological complications stress. Cannabidiol exogenous cannabinoid enhancer could useful have been seven double-blind placebo controlled clinical trials CBD on combined total 232 participants partially study 120 participants. All showed was significantly reducing non-inferior to pharmaceutical comparators, when included. trial results are supported established mechanisms action (including increased N-arachidonylethanolamine levels) extensive real-world preclinical evidence effectiveness treating

Язык: Английский

Процитировано

14

The Relationship Between Cannabis, Cognition, and Schizophrenia: It’s Complicated DOI
Hakan Kayır,

Jessica Ruffolo,

Patrick McCunn

и другие.

Current topics in behavioral neurosciences, Год журнала: 2022, Номер unknown, С. 437 - 461

Опубликована: Янв. 1, 2022

Язык: Английский

Процитировано

9

Sex-Dependent Synergism of an Edible THC: CBD Formulation in Reducing Anxiety and Depressive-like Symptoms Following Chronic Stress DOI
Enzo Pérez-Valenzuela, Roger Hudson, Taygun C. Uzuneser

и другие.

Current Neuropharmacology, Год журнала: 2023, Номер 22(12), С. 2059 - 2078

Опубликована: Сен. 13, 2023

: Cannabis has shown therapeutic potential in mood and anxiety-related pathologies. However, the two primary constituents of cannabis, cannabidiol (CBD) Δ-9-tetrahydrocannabinol (THC) produce distinct effects on molecular pathways neural circuits associated with affective disorders. Moreover, it been proposed that combination THC: CBD may have unique synergistic properties. In present study, a 1:100 ratio edible formulation were tested behavioural, neuronal assays for anxiety depressive-like endophenotypes. Adult male female Sprague-Dawley rats stressed 14 days. Then, three weeks, open field, elevated plus maze, light/dark box, social interaction, sucrose preference, forced swim test performed 90 minutes after acute consumption (30 mg/kg), THC (0.3 or THC:CBD. After behavioural tests, vivo, electrophysiological analyses ventral tegmental area prefrontal cortex (PFC). Furthermore, western-blot experiments examined expression biomarkers disorders, including protein kinase B (Akt), glycogen synthase kinase-3 (GSK-3), BDNF, mTOR, D1, D2 receptor nucleus accumbens (NAc) PFC.Edible THC:CBD produces significant anxiolytic antidepressant only rats. most cases, had stronger than either phytochemical alone. These are alterations Akt/GSK3 D2-R NAc BDNF PFC. reverses chronic stress-induced PFC activity. findings demonstrate novel formulations stress-related

Язык: Английский

Процитировано

4

Phytocannabinoids in neuromodulation: From omics to epigenetics DOI
Subhadip Banerjee,

Debolina Saha,

Rohit Sharma

и другие.

Journal of Ethnopharmacology, Год журнала: 2024, Номер 330, С. 118201 - 118201

Опубликована: Апрель 26, 2024

Язык: Английский

Процитировано

1

Biobehavioral Interactions between Endocannabinoid and Hypothalamicpituitary- adrenal Systems in Psychosis: A Systematic Review DOI
Marco Colizzi, Riccardo Bortoletto,

Giulia Antolini

и другие.

Current Neuropharmacology, Год журнала: 2023, Номер 22(3), С. 495 - 520

Опубликована: Авг. 3, 2023

Background: The diathesis-stress paradigm and the cannabinoid-hypothesis have been proposed as possible pathophysiological models of schizophrenia. However, they historically studied independently each other. Objective: This PRISMA 2020-compliant systematic review aimed at reappraising interplay between hypothalamic-pituitary-adrenal (HPA) axis endocannabinoid (eCB) system in psychosis- spectrum disorder risk outcome. Methods: All outcome clinical studies, concomitantly evaluating two systems psychosis-spectrum different stages illness, were gathered from electronic databases (Pubmed, Web Science, Scopus), discussed. Results: 41 eligible outputs extracted, focusing on least a biological measure (9 HPA-related studies: 4 eCB-interventional, 1 HPA-interventional, both HPA-interventional non-interventional, 3 non-interventional; 2 eCB-related non-interventional), environmental measures only (29 eCB- interventional, 28 genetic (1 study: non-interventional). Independent contributions aberrancies to physiopathology psychosis confirmed. Also, concomitant alterations systems, either genetically defined (e.g., CNR1 variation), biologically determined dysfunctional HPA or signaling), behaviorally imputed cannabis use, stress exposure, response), consistently reported psychosis. Further, complex biobehavioral perturbation was revealed not within use affecting eCB tone, exposure axis), but also across THC axis, childhood trauma signaling). Conclusion: There is need study systems’ mechanistic contribution order establish more refined relevance.

Язык: Английский

Процитировано

3